China-based Zephyrm Bioscience Limited, a biopharmaceutical company specializing in the development of novel pluripotent stem cell (PSC) derived cell therapies, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Details of the offering have not been disclosed at this stage.
Established in 2017, Zephyrm Bio is among the pioneers in China with clinical approvals for PSC-derived cell therapies and is currently the only company with multiple PSC-derived cell therapy assets at Phase II stages. The company’s product pipeline includes core product ZH901 and lead products ZH903, ZH902, and ZH906. ZH901 is currently undergoing Phase II clinical studies for acute exacerbation of interstitial lung disease (AE-ILD), acute graft-versus-host disease (aGVHD), meniscus injury, and acute respiratory distress syndrome (ARDS). ZH903 and ZH902 are subjects of investigator-initiated trials (ITTs) for Parkinson’s disease and dry age-related macular degeneration (AMD), respectively.
In terms of financials, Zephyrm Bio reported net losses of RMB 196 million in 2023 and RMB 237 million in the first half of 2024, along with research and development (R&D) expenses of RMB 103 million and RMB 59 million for the respective periods. – Flcube.com
